NasdaqGS:PGNYHealthcare
Does Progyny’s 2025 Rally Match Its Fertility Growth Story and Cash Flow Outlook?
If you are wondering whether Progyny is still a smart way to play the long term growth of fertility benefits, you are not alone and the numbers give us plenty to unpack.
The stock has quietly climbed 0.6% over the last week and 1.2% over the past month, but the real eye catcher is its 47.5% year to date gain and 84.4% return over the last year despite still being down over 3 and 5 years.
Behind that rebound, Progyny has continued expanding its roster of large employer clients and deepening...